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Abstract
Background: A functional blood supply is essential for tumor growth and proliferation. However,
the mechanism of blood vessel recruitment to the tumor is still poorly understood. Ideally, a
thorough molecular assessment of blood vessel cells would be critical in our comprehension of this
process. Yet, to date, there is little known about the molecular makeup of the endothelial cells of
tumor-associated blood vessels, due in part to the difficulty of isolating a pure population of
endothelial cells from the heterogeneous tissue environment.
Methods:  Here we describe the use of a recently developed technique, Expression
Microdissection, to isolate endothelial cells from the tumor microenvironment. The methylation
status of the dissected samples was evaluated for GSTP1 and RARβ2 promoters via the QMS-PCR
method.
Results: Comparing GSTP1 and RARβ2 promoter methylation data, we show that 100% and 88%
methylation is detected, respectively, in the tumor areas, both in epithelium and endothelium. Little
to no methylation is observed in non-tumor tissue areas.
Conclusion: We applied an accurate microdissection technique to isolate endothelial cells from
tissues, enabling DNA analysis such as promoter methylation status. The observations suggest that
epigenetic alterations may play a role in determining the phenotype of tumor-associated
vasculature.
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Background
Recently, the molecular study of the tumor microenviron-
ment has taken a dramatic turn. It has now been shown in
three different tissue types, breast, colon and prostate, that
the cellular microenvironment surrounding the tumor
epithelium actually demonstrates similar epigenetic
changes to those found in the tumor cells [1-3]. Once
believed to be genetically normal, evidence shows that the
supporting cast of cells shares some methylation changes
with the tumor cells themselves [1-3]. The meaning of
these changes is not yet clear, nor is it understood how
they may affect and/or support tumor progression.
While epigenetic changes have been identified in stroma,
fibroblasts, and the colorectal mucosa, there has not been
an evaluation of tumor-associated endothelial cells [1-3].
This is due in part to the difficulty in obtaining a pure
population of endothelial cells from tissues for analysis.
Endothelial cells are small, ~1 µm in diameter, and thus
are not amenable to precise microdissection with current
commercially available techniques. Other methods for
isolating endothelial cells, such as antibody labeled mag-
netic beads and fluorescence activated cell sorting (FACS),
require large amounts of fresh tissue and long processing
times [4]. Such approaches may in themselves alter the
endothelial cells, making it difficult to assess the baseline
characteristics that were present in the tumor microenvi-
ronment.
To overcome this barrier, we adapted the newly described
microdissection technique, Expression Microdissection
(xMD), for the isolation of endothelial cells in prostate tis-
sue [5]. Using xMD, we specifically procured endothelial
cells from ethanol-fixed, paraffin-embedded whole
mount prostate specimens containing both tumor and
normal areas. Through the use of two antibodies for the
detection of the endothelial cell population, CD31 and
Factor VIII, we were able to dissect the endothelial cells
away from the prostate. The goal was then to determine if
endothelial cells within the tumor microenvironment
demonstrated similar changes in promoter methylation to
those typically seen in prostate tumor epithelial cells. Glu-
tathione S-Transferase P1 (GSTP1) and Retinoic Acid
Receptor 2 (RARβ2) were selected as markers given that
their methylation has been previously shown to be more
prevalent in prostate cancer cells [6-8]. Studying eight
prostate cases, we demonstrate that indeed methylation of
GSTP1 and RARβ2 in tumor-associated endothelium was
similar to that of microdissected tumor epithelium. More-
over, the methylation rate was significantly higher in the
tumor-associated endothelium compared to that of
endothelial cells dissected from areas of normal prostate.
Methods
Tissue specimens/cell culture
Ethanol fixed paraffin-embedded prostate tumor speci-
mens were obtained from eight different patients under
Institutional Review Board (IRB) approved clinical proto-
cols. Tissue was obtained from eight separate prostate can-
cer patients with clinically localized prostate cancer
(organ-confined) who were treated by curative radical
prostatectomy at the NIH Clinical Center and the
National Naval Medical Center, Bethesda, MD.
LNCaP and PZ-HPV7 prostate cancer cell lines were
obtained from American Type Culture Collection (Rock-
ville, Maryland). LNCaP cells were maintained in RPMI
1640 medium (GIBCO-BRL, Invitrogen Corp., Carlsbad,
CA) containing L-glutamine (GIBCO-BRL, Invitrogen
Corp., Carlsbad, CA), 1% Antibiotics (GIBCO-BRL, Invit-
rogen Corp., Carlsbad, CA) and 10% heat-inactivated fetal
bovine serum (FBS) (Gemini, Woodland, CA). PZ-HPV7
cells were maintained in K-SFM (Keratinocyte- Serum
Free-Medium) (GIBCO-BRL, Invitrogen Corp., Carlsbad,
CA) containing L-glutamine (GIBCO-BRL, Invitrogen
Corp., Carlsbad, CA), 50 mg/ml BPE (GIBCO-BRL, Invit-
rogen Corp., Carlsbad, CA), 5 ng/ml EGF (GIBCO-BRL,
Invitrogen Corp., Carlsbad, CA), and 1% Antibiotics
(GIBCO-BRL, Invitrogen Corp., Carlsbad, CA). The cul-
tures were done at 37°C, 5% CO2 in a humidified atmos-
phere.
Expression microdissection
Eight-micron thick histological sections were mounted on
charged slides. Prior to immunohistochemistry, the pros-
tate tissue was de-waxed and rehydrated following stand-
ard techniques[9]. The DAKO Envision (+) System with
diaminobenzidine (DAB) (DAKO/Cytomation, Carpinte-
ria, CA) was used for immunohistochemistry staining fol-
lowing manufacturer's instructions, unless otherwise
noted.
For endothelial cell staining, the combination of Mouse
Anti-CD31 Ab-1 (JC/70A) 1:50 dilution (Neomarkers,
Fremont, CA) and Rabbit Anti-Factor VIII 1:50 dilution
(Zymed Laboratories, San Francisco, CA) was used. All
antibodies were diluted in DAKO/Cytomation Antibody
diluent with background reducing components (DAKO/
Cytomation, Carpinteria, CA). The anti-mouse secondary
antibody was incubated for 30 minutes first and then the
anti-rabbit secondary antibody was incubated for an addi-
tional 30 minutes. The DAB solution was made at 3x the
recommended concentration and incubated on the sec-
tions for 10 minutes. DAB enhancer (Zymed Laboratories,
San Francisco, CA) was applied to the tissues for 3 min-
utes. The slides were not counterstained. Sections were
then dehydrated through graded alcohols and xylenes and
allowed to air dry.Journal of Translational Medicine 2006, 4:13 http://www.translational-medicine.com/content/4/1/13
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For the epithelial dissections a 1:50 dilution of the Mouse
Anti-Cytokeratin AE1/AE3 (DAKO/Cytomation, Carpin-
teria, CA) was used.
The laser system was an Arcturus Pix Cell II with the fol-
lowing parameters for the endothelium dissections:
power = 70–100 mW, duration 35–50 milliseconds,
repeat t = 1.2 seconds, target = 0.300V, current 25.0 mL,
spot size = 7.5 µm and temperature 24°C. The parameters
for the epithelium dissections were as above, except lower
powers (30–50 mW) and durations (15–25 milliseconds)
were used.
For each patient case, four dissected samples were gener-
ated; normal epithelium, tumor epithelium, endothelium
outside the tumor area and tumor-associated endothe-
lium.
Bisulfite modification and QMS-PCR
The samples were digested overnight in 25 µl proteinase K
buffer (10 mM Tris, pH 8.0, 1 mM EDTA, 1% Tween-20,
and 1 mg/ml proteinase K). After 10 minute boiling, the
DNA was directly used for the modification reactions.
Gene specific hypermethylation status of GSTP1 and
RARβ2 was determined using real-time (quantitative)
methylation PCR (QMS-PCR) as previously described
based on the Taqman Chemistry (Applied Biosystems,
Foster City, CA) [7]. The primer and probe sequences have
been previously published [8]. The beta-actin gene
(ACTB) was used as an internal reference control.
The assays were carried out in a reaction volume of 10 µl
in 96-well plate in an Applied Biosystems 7900 Sequence
Detector (Perkin-Elmer, Foster City, CA). Each sample was
run in triplicate and only samples with an internal refer-
ence Ct score under 42 were included in the analysis. The
final reaction samples consisted of 300 nM of each primer
and 100 nM probe, 1 × Taqman Universal Master Mix, No
AmpErase UNG (Applied Biosystems, Foster City, CA).
The PCR conditions were 95°C for 2 min, followed by 50
cycles at 95°C for 15 sec and 60°C for 1 min. Serial dilu-
tions from 1 ng to 0.01 ng of methylated and unmethyl-
ated DNA (LNCaP prostate cancer and PZHPV7 normal
prostate epithelial cell lines, respectively) was run on each
plate as standards, as well as water blanks for no template
controls. The assessment of percent gene methylation was
computed using the standard curve method, as previously
described [7]. The ratios of gene methylation relative to
total amount of DNA were computed by extrapolation
from standard curve of LNCaP standards (GSTP1 and
RARβ2 are fully methylated in LNCaP cells). The percent-
ages were derived using the following formula: ng gene
(average value across triplicates)/ng ACTB (average value
across triplicates)*100.
Immunohistochemistry of the Prostate Figure 1
Immunohistochemistry of the Prostate. Representative 
photos of the immunohistochemistry staining of the epithe-
lium (A) and endothelium (B) of the same area of tumor 
using diaminobenzidine staining. Panel C is a higher magnifica-
tion of the endothelial staining to better demonstrate the 
dark staining of the endothelial cells.Journal of Translational Medicine 2006, 4:13 http://www.translational-medicine.com/content/4/1/13
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Results
Dissection of ethanol-fixed paraffin embedded whole 
mount prostate cancer specimens for DNA extraction
Dissections were carried out utilizing the newly developed
technique, xMD [5]. Briefly, xMD employs the use of a tar-
geting moiety, such as an antibody, to define the cell type
or component to be dissected. A histological tissue section
is stained via a standard immunohistochemistry protocol
using diaminobenzidine (DAB) as the chromogen. The
tissue is then covered with a contrast sensitive film and the
area of interest on the slide, i.e. tumor or normal, is irra-
diated with an infrared laser procuring only the immuno-
defined cells. Through this process it is possible to obtain
high-quality precise dissections without the introduction
of human targeting error.
Since endothelial cells had not been dissected previously
with this method, it was necessary to optimize the immu-
nohistochemical staining parameters for the adequate
activation of the film. Previous work had demonstrated
adequate immunohistochemical staining for dissection of
epithelium using only single antibodies[5]. However,
endothelial cells represent a much less abundant cell pop-
ulation comprised of only a single layer. Therefore, it was
found that a combination of CD31 (1:50 dilution) and
Factor VIII (1:50 dilution) antibodies was required to
obtain strong enough staining for dissection while main-
taining a minimal background. Figure 1 displays a repre-
sentative prostate tissue stained with epithelium and
endothelium specific markers after optimization. Using
xMD, both the endothelium and epithelium were dis-
sected for the neoplastic and normal areas of the prostate
on the same slide for each individual patient specimen.
Figure 2 shows the tissue before dissection, after dissec-
tion and the procured dissected cells on the film. The dark
staining of the endothelium is required to allow optimal
dissection of the endothelial cells (Figure 2A). After dis-
section, the dark staining is no longer visible indicating
that the endothelial cells were captured on the film (Fig-
ure 2B). The darkly stained endothelium is clearly visible
on the film, maintaining its original architecture (Figure
2C). Figure 2D and 2E show further examples of xMD
films with captured endothelial cells. It is thus possible to
procure complete endothelial linings away from the ves-
sels of the sections using this method of microdissection
in a rapid, high-throughput manner. Furthermore, since
tissue architecture is maintained, visual confirmation of
adequate capture is possible.
Increased methylation in endothelial and epithelial tissues 
in tumor areas
DNA was isolated from the dissected cell populations and
tested for promoter methylation at GSTP1 and RARβ2
using Quantitative Methylation-Sensitive PCR (QMS-
PCR) technology. Table 1 summarizes the results of the
methylation status for the eight patients studied. For
GSTP1, all samples demonstrated methylation in both the
tumor-associated endothelium and tumor epithelium.
None of the normal epithelium samples demonstrated
methylation at GSTP1 and only two cases demonstrated
methylation in the normal endothelium. In the tumor tis-
sue, methylation was identified in seven out of the eight
specimens for RARβ2 in both the endothelium and epi-
thelium, while there was no methylation in the normal
tissue for either cell population. To evaluate this further,
the percent of methylation for the endothelium and epi-
thelium was semi-quantified utilizing the standard curve
method as previously described [7] (Table 2). While
methylation was identified in both the epithelium and
endothelium, the percentage of methylation varied
between the two cell types. In three patients, we observed
that the tumor endothelium demonstrated a higher
Expression Microdissection of the Prostate Endothelium Figure 2
Expression Microdissection of the Prostate Endothe-
lium. Representative photos of the endothelial stained slide 
before xMD dissection (A), after dissection (B) and the film 
used for dissection (C). In panel B, the darkly stained 
endothelial cells have been procured from the slide. Panels D 
and E are additional photos of endothelial cell dissections 
using xMD.Journal of Translational Medicine 2006, 4:13 http://www.translational-medicine.com/content/4/1/13
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degree of methylation when compared to the tumor epi-
thelium. For example, the endothelium in the tumor area
of patient 7 demonstrated 100% methylation at GSTP1,
while the tumor epithelium only showed 10% methyla-
tion. These findings, together with the visualization of the
dissected fields, support the selectivity of these dissections
and the purity of the population obtained. A representa-
tive gel of methylation specific PCR products from two of
the prostate cases is shown in Figure 3.
Discussion
Epigenetic changes have been well documented in the
progression of prostate cancer [10]. In particular, GSTP1
and RARβ2 have been found to be highly methylated
within the tumor epithelium of the prostate [6,11]. While
there has been significant attention paid to the study of
tumor cell methylation, few groups have evaluated meth-
ylation changes of the tumor-associated stromal compart-
ment. Several cell types make up the stromal elements
within the tumor microenviroment, including fibroblasts,
inflammatory cells and endothelial cells.
The phenotype of tumor-associated endothelium differs
dramatically from that of endothelial cells in non-tumor
tissue[12]. Recent studies have also revealed gene expres-
sion changes between tumor-associated endothelial cells
as compared to their counterparts in adjacent areas of nor-
mal tissue [4]. Although, epigenetic differences such as
changes in methylation patterns have not been demon-
strated for endothelial cells. If such differences exist, a bet-
ter understanding of differential gene expression, through
promotor modulation may be possible.
Using a newly developed microdissection technique,
xMD, we were able to procure pure populations of
endothelial cells from both the tumor microenvironment
and normal areas of the prostate from the same patient
specimens. The isolation of such small targets from com-
plex human tissues has been a major obstacle when trying
to analyze these cells on a molecular level. Subsequently,
we identified, via bisulfite modification and QMS-PCR
analysis, promoter methylation changes between tumor-
associated endothelium and normal endothelium for
GSTP1 and RARβ2. The observed prevalence of methyla-
tion in the tumor-associated and normal endothelial cell
populations reflected the differences seen between the
tumor epithelium and normal epithelium. However,
there were also finer differences in methylation prevalence
observed between tumor epithelium and tumor endothe-
lium within several cases.
One issue of concern when evaluating the percent methyl-
ation was the possibility of contamination with tumor
epithelial cells in the endothelial cell dissections. This is
an important issue, since a false positive result may be
observed if significant numbers of tumor epithelial cells
were inadvertently captured during dissection. Since this
is a DNA based method, it is difficult to obtain a discrim-
inating molecular marker providing conclusive evidence
of cell purity. In addition, the tissue studied was ethanol-
fixed paraffin-embedded limiting our ability to perform a
robust mRNA analysis. However, several factors support
the integrity of the samples including; microscopic visual-
ization of the procured endothelial cells, the lack of visual
evidence of contamination by other cell populations, and
the observation of varying levels of methylation between
the tumor-associated endothelium and tumor epithelium
within the same case, as seen in patients 2, 6, and 7. This
is especially evident in cases where the percent endothelial
cell methylation was higher than the percent epithelial
cell methylation. Additionally, the specificity of the xMD
technique was demonstrated previously by the ability to
dissect specific small targets, such as nuclei and basal cells
in prostate tissue [5].
It is also interesting to note that two patient samples dis-
played 100% methylation for GSTP1 in the isolated nor-
mal endothelial cell population. Considering this finding,
we surveyed the tissue specimens for histological features
that might be unique to those cases, including the amount
and type of inflammatory infiltrate in the stroma. None
were observed. A mild, focal chronic inflammatory infil-
trate was seen in all cases. Hence, the significance of this
finding remains unclear.
Table 1: Summary data of gene methylation in tumor and normal epithelium and endothelium from 8 whole mount prostate 
specimens.
Histology Tissue Gene Methylation Positive* No. (%)
GSTP1 RARβ2
Tumor (n = 8) Endothelium 8 (100%) 7 (88%)
Epithelium 8 (100%) 7 (88%)
Normal (n = 8) Endothelium 2 (25%) 0 (0%)
Epithelium 0 (0%) 0 (0%)
*Gene methylation determined by QMS-PCR and considered positive if any methylation observed.Journal of Translational Medicine 2006, 4:13 http://www.translational-medicine.com/content/4/1/13
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While others have evaluated the effect of promoter meth-
ylation on gene expression in endothelial cells, this is the
first report of differential endothelial promoter methyla-
tion in the tumor microenvironment. Growing evidence
has shown a possible field effect of the tumor cells on
their surrounding microenvironment [1-3]. The fact that
the tumor-associated vessels demonstrate differential
methylation when compared to normal vessels suggests
that methylation may play some role in establishing the
unique phenotype of the tumor vasculature. Such an
observation, if supported by further studies, could allow
for the identification of new targets for the development
of therapies directed to the tumor vasculature.
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Table 2: Gene Methylation in Tumor and Normal Epithelial and 
Endothelial Tissue from 8 Prostate Cancer Patients Determined 
from Whole Mount Prostate Specimens.
Patient Histology Tissue Type GSTP1 RARβ2
1 Normal Endothelium 0% 0%
Normal Epithelium 0% 0%
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7 Normal Endothelium 0% 0%
Normal Epithelium 0% 0%
Tumor Endothelium 100% 100%
Tumor Epithelium 10% 0%
8 Normal Endothelium 100% 0%
Normal Epithelium 0% 0%
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